Jang YJ - Search Results

1

Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma.

Jang YJ, Kim EJ, Kim HD, Kim KP, Ryu MH, Park SR, Choi WM, Lee D, Choi J, Shim JH, Kim KM, Lim YS, Lee HC, Ryoo BY, Yoo C. Jang YJ, et al. J Cancer Res Clin Oncol. 2023 Aug;149(10):7547-7555. doi: 10.1007/s00432-023-04704-3. Epub 2023 Mar 27. J Cancer Res Clin Oncol. 2023. PMID: 36971796

2

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.

Jang YJ, Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC. Jang YJ, et al. BMC Cancer. 2021 Jun 26;21(1):731. doi: 10.1186/s12885-021-08472-6. BMC Cancer. 2021. PMID: 34174841 Free PMC article.

3

Association of EGFR mutations in second primary lung cancer and HER2 expression in breast cancer survivors.

Jang YJ, Kim SY, Jung HK, Kim HR, Kim CH, Lee HR, Kang HJ, Yang SH, Seol H, Na II. Jang YJ, et al. Transl Cancer Res. 2021 Dec;10(12):5204-5211. doi: 10.21037/tcr-21-1235. Transl Cancer Res. 2021. PMID: 35116370 Free PMC article.

4

Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment.

Jang YJ, Hyun DG, Ji W, Choi CM, Yoon S, Lee DH, Kim SW, Lee JC. Jang YJ, et al. Cancer Res Treat. 2023 Apr;55(2):468-478. doi: 10.4143/crt.2022.1342. Epub 2022 Nov 28. Cancer Res Treat. 2023. PMID: 36470259 Free PMC article.

5

Radioimmunotherapy with ¹³¹ I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma.

Jang YJ, Lim SM, Lee I, Byun BH, Lim I, Kim BI, Choi CW, Lee SS, Suh C, Yoon DH, Kim I, Nam SH, Lee MH, Won JH, Kong JH, Jeong SH, Oh SJ, Park KW, Han JJ, Song MK, Yang SH, Na II, Lee HR, Shin DY, Kang HJ. Jang YJ, et al. Asia Pac J Clin Oncol. 2023 Dec;19(6):690-696. doi: 10.1111/ajco.13932. Epub 2023 Mar 13. Asia Pac J Clin Oncol. 2023. PMID: 36915956

6

A Phase II Study of ¹³¹I-rituximab for Patients With Relapsed or Refractory Marginal Zone Lymphoma.

Jang YJ, Lim SM, Lee I, Byun BH, Lim I, Kim BI, Choi CW, Lee SS, Yang SH, Na II, Lee HR, Shin DY, Kang HJ. Jang YJ, et al. Clin Med Insights Oncol. 2023 Dec 11;17:11795549231218082. doi: 10.1177/11795549231218082. eCollection 2023. Clin Med Insights Oncol. 2023. PMID: 38090634 Free PMC article.

7

Secondary hematological malignancies in patients with sarcoma: A single‑center retrospective study.

Jang YJ, Jeong HK, Kong CB, Song WS, Cho WH, Jeon DG, Kim H, Yang SH, Na II, Lee HR, Kang HJ. Jang YJ, et al. Oncol Lett. 2024 Mar 14;27(5):211. doi: 10.3892/ol.2024.14344. eCollection 2024 May. Oncol Lett. 2024. PMID: 38572064 Free PMC article.

8

CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience.

Jang YJ, Jeong JH, Kim JE, Ahn JH, Jung KH, Kim SB. Jang YJ, et al. J Breast Cancer. 2022 Feb;25(1):49-56. doi: 10.4048/jbc.2022.25.e1. Epub 2021 Dec 15. J Breast Cancer. 2022. PMID: 35133090 Free PMC article.

9

Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer in vitro.

Jang Y, Lee WS, Sai S, Kim JY, Kim JK, Kim EH. Jang Y, et al. Oncol Lett. 2022 Aug 11;24(4):338. doi: 10.3892/ol.2022.13458. eCollection 2022 Oct. Oncol Lett. 2022. PMID: 36039063 Free PMC article.

10

Saxatilin, a snake venom disintegrin, regulates platelet activation associated with human vascular endothelial cell migration and invasion.

Jang YJ, Jeon OH, Kim DS. Jang YJ, et al. J Vasc Res. 2007;44(2):129-37. doi: 10.1159/000098519. Epub 2007 Jan 11. J Vasc Res. 2007. PMID: 17215584

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

941 results

Search Page